| Literature DB >> 26656517 |
William J Gradishar1, Benjamin O Anderson1, Ron Balassanian1, Sarah L Blair1, Harold J Burstein1, Amy Cyr1, Anthony D Elias1, William B Farrar1, Andres Forero1, Sharon Hermes Giordano1, Matthew Goetz1, Lori J Goldstein1, Clifford A Hudis1, Steven J Isakoff1, P Kelly Marcom1, Ingrid A Mayer1, Beryl McCormick1, Meena Moran1, Sameer A Patel1, Lori J Pierce1, Elizabeth C Reed1, Kilian E Salerno1, Lee S Schwartzberg1, Karen Lisa Smith1, Mary Lou Smith1, Hatem Soliman1, George Somlo1, Melinda Telli1, John H Ward1, Dottie A Shead1, Rashmi Kumar1.
Abstract
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.Entities:
Mesh：
Year: 2015 PMID： 26656517 DOI： 10.6004/jnccn.2015.0176
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908